Tumor Microenvironment and Genes Affecting the Prognosis of Temozolomide-Treated Glioblastoma.

English summary

This study explored tumor-microenvironment features and transcriptomic biomarkers associated with prognosis in patients with glioblastoma (GBM) treated with temozolomide (TMZ). Public datasets from TCGA and GEO were analyzed using CIBERSORTx, weighted gene co-expression network analysis (WGCNA), differential-expression analysis, and Cox proportional-hazard survival analysis.

Key points

• Inflammatory microglial cells, dendritic cells, myeloid cells, and glioma stem cells were highly expressed in GBM tissue.
• ACP7, EPPK1, PCDHA8, RHOD, DRC1, ZIC3, and PRLR were significantly associated with survival in TMZ-treated GBM patients.
• Although the listed genes had previously been linked to glioblastoma or other cancers, ACP7 was identified as a novel candidate gene associated with GBM prognosis.

Audience

This summary is intended for clinicians, researchers, and advanced students interested in GBM molecular prognosis, the tumor microenvironment, TMZ response, and precision-medicine biomarkers.

Scope and limitations

The findings are associations derived from computational analyses of publicly available TCGA and GEO datasets. Based on the supplied text, the causal roles of the candidate genes, their clinical predictive performance, and their practical utility for identifying TMZ resistance cannot be established; independent-cohort and experimental validation are needed.

Research context

The study is thematically connected to precision-medicine research that uses tumor-microenvironment and gene-expression data to investigate candidate biomarkers of treatment response and prognosis.